sglt2 inhibitors vs glp-1 Combining Receptor Agonists and in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy Disparities in SGLT2 Inhibitor or

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, whereas semaglutide only targets the GLP-1 receptors

This highlights the real post-GLP-1 problem: not weight loss but behavioral stabilization after intervention

Introduction Lymphedema is a major public health issue for many women undergoing breast cancer treatment

Determination of secreted GLP-1 concentrations GLUTag cells seeded at a density of 8 10 4 cells/well in a 48-well plate and incubated for 48 h were washed and incubated with Krebs-Ringer bicarbonate buffer containing 0.1% bovine serum albumin and 5.5 mM glucose for 30 min